MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Crinetics Pharmaceuticals Inc

Closed

SectorHealthcare

31.09 -5.84

Overview

Share price change

24h

Current

Min

30.74

Max

33.1

Key metrics

By Trading Economics

Income

-16M

-97M

Sales

361K

361K

Profit margin

-26,807.202

Employees

437

EBITDA

-17M

-110M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+127.27% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

-68M

3.1B

Previous open

36.93

Previous close

31.09

News Sentiment

By Acuity

76%

24%

347 / 376 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lip 2025, 21:01 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 20:46 UTC

Earnings

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lip 2025, 20:39 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 20:36 UTC

Earnings

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lip 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lip 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 lip 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lip 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lip 2025, 18:24 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lip 2025, 18:19 UTC

Earnings

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lip 2025, 18:11 UTC

Acquisitions, Mergers, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lip 2025, 18:11 UTC

Earnings

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lip 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lip 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lip 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 16:04 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lip 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 lip 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lip 2025, 15:47 UTC

Market Talk
Earnings

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Comparison

Price change

Crinetics Pharmaceuticals Inc Forecast

Price Target

By TipRanks

127.27% upside

12 Months Forecast

Average 72.5 USD  127.27%

High 97 USD

Low 36 USD

Based on 11 Wall Street analysts offering 12 month price targets forCrinetics Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

30.39 / 33.46Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

347 / 376 Ranking in Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.